PR in the Philippines

EQS Newswire / 02/04/2025 / 12:32 UTC+8 (Macao – April 2, 2025) – The integration of the Greater Bay Area (GBA) continues to accelerate, driven by advancements in infrastructure, deep tech collaboration, enhanced convenience for residents, and streamlined regulatory frameworks. On April 2, 2025, Guangzhou Metro, Ant Group, and MACAU Pass announced a partnership, enabling Macao residents to seamlessly use MPay for travel across Guangzhou’s entire public transportation network—including metro, buses, and ferries—as well as the Foshan Metro. Powered by Alipay+, Ant International’s cross-border mobile payment and digitalization solution, this initiative makes commuting within the GBA’s "Smart Living Circle" more convenient than ever.      MPay users can activate the service by navigating to the "Cross-Border Zone" within the app and selecting "Guangzhou Metro" to generate a ride QR code. Payments are processed in MOP, with exclusive fare discounts under Guangzhou's public transport policy: a 20% reduction after spending RMB 80 in a month, increasing to 50% upon reaching RMB 200.    As digital innovation continues to reshape daily life, the GBA is witnessing an accelerated integration of smart services. Since the launch of MPay’s Cross-Border Zone in August 2024, Macao residents have been able to use their familiar e-wallet for seamless transactions across the Chinese mainland. With access to over 70 cross-border mini-programs, users can enjoy personalized services and exclusive discounts across various sectors, including transportation, dining, and shared rentals.   Sun Ho, Chairman and CEO of MACAU Pass, emphasized: "As a one-stop super app, MPay now supports a wide range of cross-border scenarios, spanning payments, transportation, and lifestyle services. Our integration with Guangzhou Metro marks a significant milestone for cross-border commuting, further advancing the GBA’s ‘1-Hour Living Circle.’ We're pioneering digital solutions in the Greater Bay Area using advanced technologies, creating replicable models for mainland expansion and enhanced regional connectivity."   In recent years, policy reforms have streamlined entry for foreign nationals and Hong Kong/Macao residents. A spokesperson from Guangzhou Metro Group remarked: "Guangzhou and Macao are at the heart of the GBA, with strong intercity ties and metro systems as the backbone of daily commutes. Our partnership with Alipay+ and MPay enhances travel convenience for Macao residents while deepening regional cooperation. Looking ahead, we aim to unify transit systems with a nationwide QR code for urban rail, advancing a seamless ‘One Ticket, One Network’ strategy across the GBA."   Venetia Lee, Greater China General Manager of Ant International, said: "Alipay+ is playing a key role in deepening GBA integration. Beyond improving cross-border connectivity, this initiative upgrades residents' consumption pattern from traditional spending to ‘experience-driven economy.’ More importantly, it enhances digital connectivity with warmth, making cross-border services resonate in daily life."   02/04/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS Newswire / 02/04/2025 / 11:56 UTC+8 Sinohealth Holdings (2361.HK) delivered a solid and progressive financial performance in 2024: annual revenue reached RMB404 million, up 1.9% year-over-year; net profit stood at RMB112 million, up 10.8% year-over-year.   Against the backdrop of AI reshaping productivity in the healthcare industry, this result not only demonstrates the Company's strong execution in accelerating its AI strategy but also confirms its deep deployment and high-value technical barriers in vertical healthcare scenarios.   Sinohealth's success is no accident - it represents the inevitable outcome of converging factors including data accumulation, technological innovation, ecological layout, and policy dividends.   1.Dual Catalysts: New Value Opportunities Amid Rising Eastern Technology and Healthcare Stimulus   2024 saw a "rising East, falling West" global capital market landscape - the revaluation wave of Eastern tech assets centered in China coincided with intensive policy rollouts supporting consumption and healthcare industry development. Leading enterprises with both technological strength and healthcare scenario advantages usher in historic windows for value revaluation.   As a company whose strategic layout aligns deeply with these two market themes, Sinohealth is poised to capture new growth drivers from this dual opportunity.   From the perspective of tech asset revaluation, Chinese tech companies are transitioning from "scenario adopters" to "standard setters" amid global industrial chain restructuring.   As a leader in China's healthcare data technology sector, Sinohealth has maintained continuous R&D investment, particularly achieving breakthroughs in frontier fields like AI, big data, and healthcare scenario integration. Financial reports show that as of end-2024, the Company employed 304 staff with medical and pharmaceutical expertise and 140 with computer science backgrounds, while R&D expenditure increased 6% year-over-year.   Benefiting from its monopoly-level data infrastructure and full-chain technical barriers spanning data governance to clinical decision-making, the Company's "tech capabilities" are market-scarce. Its comprehensive ecological empowerment system has built robust resource integration capabilities, while extensive industrial partnering network create significant competitive advantages, supporting continuous valuation uplift potential.   From the healthcare consumption expansion perspective, intensified pro-consumption policies combined with population aging and consumption recovery are driving structural optimization of medication use and growing demand for quality healthcare services, continuing to improve sector fundamentals.   A recent Everbright Securities report noted that policy support plus accelerating aging are priming consumer healthcare recovery: the "Special Action Plan for Boosting Consumption" explicitly aims to enhance medical and elderly care capabilities. This policy tilt combined with demographic aging will drive concurrent growth in consumer healthcare demand and purchasing power.   In response, the Company, with its deep healthcare data technology layout, links numerous B- and C-end healthcare consumers, precisely addressing policy-driven healthcare consumption upgrade demands and seizing new growth opportunities.   Clearly, whether viewed through the lens of tech asset revaluation or healthcare policy dividends, the Company is precisely aligned with current market trends, positioned to resonate with sectoral momentum and capture alpha opportunities through its strategic advantages in beta opportunities.   2.Business Breakdown: Three-Pronged Approach Driving Ecological Growth   Sinohealth's business model can be characterized as a "three-pronged approach" - taking To B as the foundation, with To C and To R serving as incremental engines, forming an "iron triangle" structure.   To B: Strengthening Moats Through In-Hospital & Out-of-Hospital Synergy   Sinohealth's To B business remains its core revenue source and best demonstration of technical barriers and data advantages.   Innovative in-hospital business achieved significant progress over the year, with revenue surging 86.5% year-over-year to RMB48.4 million. This growth marks a strategic upgrade in product mix, opening a new growth frontier beyond mature out-of-hospital B-end businesses.     With nearly two decades of healthcare industry expertise, the Company leverages its data assets, technological advantages, and industrial ecosystems to connect out-of-hospital (pharmacy stores) and in-hospital data, building omni-channel insights capabilities covering “people, goods and venue” to provide full-chain smart digital solutions for medical product suppliers.   The Company continues enabling clients to make efficient operational decisions, achieve precise market connections, and enhance operational efficiency and growth. This win-win strategy has driven steady revenue growth and continuous client ecosystem expansion.   In 2024, its Smart Retail Cloud revenue grew 24.2% year-over-year, serving 694 enterprise clients. The core SIC system covered 2,853 pharmaceutical retail enterprises and 118,000 pharmacy stores. The system manages over 245,000 pharmacy staff and 282 million pharmacy members, with monthly active staff and members reaching 107,000 and 2.5 million respectively.   Additionally, by end-2024, its smart decision-making solutions served 661 enterprise clients, maintaining market-leading scale with continuous growth. The top 30 healthcare product suppliers accounted for 96.67% of clientele, reflecting both market leadership in out-of-hospital segments and rapid in-hospital market penetration.   To C: Explosive Growth & Emerging Monetization Models   Sinohealth's To C business is rapidly emerging as a new growth engine. Through a "light - heath management + heavy-serious illness management" model, the Company is expanding from B-end ecosystems to C-end markets, exploring private domain traffic monetization possibilities.   In health management, the Company provides smart health management cloud products through medical and physical examination institutions for physical examination users and at-risk populations for various chronic diseases, offering "Woodpecker AI-MDT" smart health management solutions covering physical examination reports interpretation, health follow-ups services for sub-healthy populations, single-disease health management services, and personalized physical examination services, so as to meet the post-examination health management needs of patients for the full process. Financial data shows that in 2024, AI-MDT services reached over 5.07 million patients, up 106% year-over-year.   In serious illness management, the Company's smart medical cloud products for oncology patients leverage the Woodpecker Multi-disciplinary Oncology Treatment Platform by adhering to authoritative clinical guidelines, precision-matching expert oncology teams, and delivering multi-disciplinary collaborative implementation solutions, significantly enhancing treatment quality and efficiency for patients.   To R: Future-Oriented Layout in Innovative Drug R&D   Sinohealth's To R business focuses on biopharmaceutical R&D, building R&D intelligent agents through collaborations with drug enterprises and CRO companies to provide smart clinical research solutions.   Encompassing the full lifecycle from clinical development to post-launch marketing, the Company offers integrated smart solutions including protocol design, intelligent systems, and operational services to innovative pharmaceutical and medical device manufacturers. The Company also integrates resources across medical institutions, innovative drug enterprises, CRO companies, CMO companies, and pharmaceutical retail enterprises to build industrial cooperation ecosystems.   Additionally, strategic investments and M&A are planned to expand its layout in the field of innovative pharmaceutical and medical devices, integrating capital and technology resources to incubate promising synergistic targets. This forward-looking layout provides strong technical reserves and ecological potential for future growth, solidifying its advantages in biopharmaceutical R&D.   3.Value Growth Logic: Scarcity + Flywheel Effect + Application Scenarios   Looking ahead, Sinohealth's core value growth logic revolves around three key areas.   First, scarcity.   As a rare "vertical healthcare large model + data services" listed entity in Hong Kong Stock Exchange, Sinohealth holds unique core asset value for its leading position in healthcare data technology.   With accelerating industry digital transformation, data and AI are becoming critical competitive factors. The Company will continue strengthening its scarcity in this field, particularly through its growing vertical healthcare large model capabilities and near-monopolistic data infrastructure advantages.   Furthermore, not only the Company holds technological advantages, but also its deep industry expertise and extensive ecological partnering network create irreplaceable market positions.     Second, flywheel effect.   Sinohealth has built a powerful growth flywheel through data accumulation, model optimization, client stickiness enhancement, and data feedback loops. This virtuous cycle not only increases client loyalty but also provides sustained long-term growth momentum.   For example, the "Tiangong-No.1" commercial data smart middleware and "Woodpecker (Zhuomuniao)" medical middleware form dual engines driving high-quality data resource systems. The Company has amassed millions of public data (medical literature, guidelines, drug inserts) and tens of millions of de-identified and annotated datasets, providing a solid foundation for Woodpecker's model training.   Meanwhile, high-quality smart solutions significantly enhance client stickiness, demonstrating strong attraction and value extraction capabilities across B- and C-end markets.   In addition, a virtuous loop has been formed through data feedback, where customers use the data generated by the Company's services to further optimize the model, and the optimized model improves service quality, thereby attracting more customers. This positive cycle not only enhances customer stickiness, but also provides sustained momentum for the Company's long-term development.   Third, application scenarios.   With policy support and accelerating AI commercialization in healthcare, Sinohealth is poised for value revaluation. Its core growth drivers will continue benefiting from deep scenario penetration capabilities.   The recent "Notice on Issuing Reference Guidelines for Artificial Intelligence Application Scenarios in the Health Industry" issued by China's National Health Commission identified 84 AI application scenarios covering full process services such as disease screening, diagnostic support, and health management. This policy provides a clear roadmap for large-scale AI+healthcare deployment, marking a strategic transition from local pilot projects to systematic implementation.   Against this backdrop, the Company is actively building intelligent agent ecosystems, creating a healthcare OS centered on "scenario penetration." Through five vertical intelligent agent matrices (medical, pharmacy, commercial, health management, R&D), the Company is embedding AI capabilities into industry microcosms, establishing a complete "data collection - model training - scenario empowerment - commercial realization" loop.   This scenario-driven technical ecological monetization path aligns with policy directions while building competitive barriers through data governance capabilities. It not only creates ongoing business opportunities but also provides catalysts for value revaluation. With its deep industry advantages and continuous innovation, the Company is well-positioned to capture market recognition and valuation uplift from policy dividends.   Additionally, its asset-light business model features a 57.8% gross margin (up 1.4pp YoY), reflecting economies of scale in ecological services and AI-driven cost efficiency potential, portending positive future profit margin expansion.   Strong cash reserves and stable core business cash flows sustain R&D innovation, enhancing operational security and growth resilience amid market uncertainties. The Company also demonstrates shareholder commitment with a 70% payout ratio, dividend yield significantly exceeding the Hang Seng Tech Index median.   In summary, Sinohealth offers near-term B-end growth visibility, mid-term C-end monetization breakthrough potential, and long-term AI healthcare ecosystem transformation upside, all supported by a high safety margin through robust dividend returns.   4.Conclusion   With "data as foundation, AI as spear," Sinohealth is driving a healthcare revolution in vertical scenarios, while demonstrating strong beta and alpha attributes amid tailwinds of China's tech asset revaluation, consumption boost and healthcare support.   The Company has secured critical positions at the "data entry" and "decision exit" points in this AI-driven transformation in medical and healthcare industry, with its valuation logic transitioning from "software service provider" to "healthcare ecosystem operator."   As market perceptions shift from "tool value" to "ecological value," a quiet value revaluation is already underway. 02/04/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS Newswire / 01/04/2025 / 18:16 UTC+8 [Hong Kong－1, April 2025] The reputable international inspection and testing company, China Leon Inspection Holding Limited (“Leon Inspection” or the “Company”, together with its subsidiaries, the "Group")(Stock code: 1586.HK) is pleased to announce that, benefiting from the robust development of the global energy and TIC industries, along with the Group’s sound strategic guidance, the Group fully leveraged its leadership in niche markets in 2024. Seizing business opportunities, the Group continued to expand its scale, with employee numbers exceeding 3,300 and networks spanning 19 countries worldwide. The Group has deepened its brand credibility, consistently enhanced operational efficiency and core competitive strengths, and steadily advanced high-quality development.   Steady growth in performance with robust overseas revenue increased In 2024, the Company recorded revenue of HK$1,263.1 million, representing a year-on-year increase of 12.9%; profit for the Year reached HK$126.0 million, representing a year-on-year increase of 3.2%; profit attributable to owners of the Company amounted to HK$82.7 million, representing a year-on-year increase of 3.4%, further consolidating its industry-leading position. The Group continued to deepen the globalized layout, while expanding its service network from major trading ports and hub cities in the Asia-Pacific region to multiple emerging markets. The Group operates 78 branches and professional laboratories worldwide, spanning 19 countries. The Group strategically seizes development opportunities in emerging markets, proactively expanding into regions such as Africa and the Middle East with its superior global service capabilities. The Group’s business presence has flourished across multiple regions. The Group achieved outstanding results in overseas market expansion, with overseas revenue increasing by 21.3% to HK$567.6 million in 2024, accounting for 44.9% of total Group revenue, injecting strong momentum into the Group's performance growth.   The commodity business achieved remarkable success, with professional service capabilities and brand credibility gaining market recognition Supported by its robust overall capabilities, exceptional technical expertise, and outstanding talent pool, the Group has become a designated inspection institution for multiple exchanges. In 2024, the Group continued to secure qualifications as a designated quality inspection institution for futures exchanges, further reinforcing its extensive experience and brand credibility in bulk commodity inspection. On 22 January 2024, the Shanghai Futures Exchange authorized the Group as its designated inspection institution for alumina futures. Having already been designated as the inspection institution for the Shanghai Futures Exchange’s key non-ferrous metals-copper, aluminum, and zinc, the Group became its designated inspection institution for alumina futures as well, further enhancing its brand recognition with non-ferrous metal clients. On 14 June 2024, the Zhengzhou Commodity Exchange designated the Group as its inspection institution for ferroalloy futures, reflecting its high recognition of the Group’s extensive experience and brand credibility in bulk commodity inspection. The Group’s testing and inspection product line continues to expand, and it has now become the leading quality inspection institution for lithium carbonate, ferroalloys, and industrial silicon. Below is the list of futures inspection qualifications obtained by the Group and its subsidiaries from major exchanges to date: Exchange Futures products Shanghai Futures Exchange Copper, aluminum, zinc, alumina, aluminum alloy Dalian Commodity Exchange Coking coal, coke, iron ore Zhengzhou Commodity Exchange Thermal coal, ferrosilicon, manganese-silicon Guangzhou Futures Exchange Industrial silicon, lithium carbonate Shanghai International Energy Exchange Bonded copper     Focus on AI-driven innovative technological advancements to intelligently usher in a new era for the TIC industry The Group is accelerating its integration into the wave of intelligent development, leveraging Al to drive technological innovation and upgrades, and leading industry advancement. The Group has taken the lead in deploying A I application technologies across its business lines, including coal, commodity services, integrated refining and chemicals, new energy, and environmental sectors. It has introduced automated spectral analysis pre-processing systems and Al-powered visual inspection devices, significantly improving automation rates in key processes and data verification efficiency. With the support of its partners, the Group has established the “Smart Testing Laboratory 3.0” and developed a blockchain-based platform for certifying testing data. Through the in-house smart test system, customers can track testing progress in real time and independently authorize report circulation, greatly enhancing service response speed. By leveraging technological innovations such as Al applications to optimize and upgrade service capabilities, the Group continuously strengthens its ability to serve top-tier clients, enhances customer loyalty and market competitiveness, and solidifies its leading position in the industry.   The Group plans to complete the global deployment of its Al system by 2025, while achieving continuous breakthroughs in areas such as establishing a cross-border AI inspection mutual recognition system, developing an Al-powered carbon emission accounting module, and creating a quality prediction model for bulk energy commodities. In the medium to long term, the Group will bolster its support for R&D innovation, continuously driving the deep integration of technologies like Al, digital twins, and blockchain into testing technologies, equipment, and laboratory management. This will facilitate the development of AI-powered unmanned testing and laboratory platforms, ultimately establishing a new paradigm of “Al-driven, human-machine collaboration” in testing and inspection.   The climate change business continued to forge ahead actively, supporting the green and low-carbon transition of the energy industry chain As one of the leading carbon asset traders in the Beijing carbon market, the Group significantly expanded its carbon asset trading volume in collaboration with clients this year, enabling more customers to meet their annual compliance obligations cost-effectively. The Group also strengthened its global operational capabilities, securing several overseas carbon asset projects during the Year to support the industry and clients in achieving sustainable lowcarbon transitions. With the progressive rollout and clarification of new global carbon market regulations, the market is poised for substantial growth. The Group is well-positioned to seize these opportunities, leveraging its internal experts, recognized a s specialists in emerging global carbon market mechanisms, and its strong brand credibility and influence among clients and governments.     Mr Li Xiangli, Chairman and Chief Executive Officer of China Leon Inspection Holding Limited stated that: “ This year, we published a Letter to Shareholders in our 2024 annual results for the first time. We fully recognized that the Group’s steady growth relies on the unwavering support of all shareholders. Through this letter, we hope to express our sincere gratitude to all investors who have steadfastly stood by the company. Guided by the core principle of long-term sustainable development, the Company remains committed to safeguarding shareholders’ interests, sharing the benefits of its economic achievements, and creating long-term value for all stakeholders. Additionally, the rapid advancement of Artificial intelligence (Al) technology is reshaping the global economic landscape in the medium to long term. In 2025, the Group designates AI as key application of the new technologies, firmly seizing the opportunities presented by the AI industry’s growth. The Group is fully embracing the AI era by cultivating AI capabilities, integrating AI resources, and continuously advancing AI progress through rapid iteration, ongoing improvement, and relentless innovation. Leveraging AI and robotics, the Group is accelerating technological innovation and upgrades, accelerating AI empowerment in business scenarios and establishing a blueprint for corporate development. The Group strives to achieve industry innovation, scale new heights, and deliver sustained, high-quality returns to shareholders.”     -END-   About China Leon Inspection Holding Limited China Leon Inspection Holding Limited (stock code: 1586. HK) was listed on the Main Board of the Stock Exchange in 2016. The Company is China’s first international leading inspection and testing company listed in Hong Kong, focusing on integrated solutions for climate change and green and low-carbon sustainable development. The Company provides global industry leaders with a wide range of one-stop services in testing, and inspection, as well as technical and consulting services around the clock, focusing on four key areas, namely commodity services, clean energy, environmental protection and climate change, empowering global industry leaders to achieve ecofriendly and low-carbon transformation. The Company continues to strengthen its global network layout, expanding its presence from major trading ports and hub cities in the Asia Pacific region to emerging markets in South America and Africa serves, and comprises 78 branches and professional laboratories globally. ESG-oriented development is a key priority for the Company’s “3+X” development strategy. Through the three main implementation dimensions of (1) ESG-Friendly+; (2) ESG+; and (3)ESG+-Focused , we have achieved our ESG development strategies, fulfilled our corporate social responsibility, and contributed to the green and low-carbon transition of the industry.   01/04/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com